Back to Investors
M

Martlet

Angel

Martlet Capital is an early-stage investor based in Cambridge, providing patient capital to deep technology and life science startups.

Portfolio

5

companies


Portfolio companies

Spotta

Spotta

Spotta develops smart pest-detection technology for continuous insect monitoring.

Nu Quantum

Nu Quantum

Nu Quantum develops hardware infrastructure to interconnect and scale quantum computers.

Psyomics

Psyomics

Psyomics builds digital mental health assessment platforms for patients and clinicians.

F

Flusso

Flusso develops miniaturised flow sensors for consumer and industrial applications.

Closed Loop Medicine

Closed Loop Medicine

Closed Loop Medicine develops integrated drug and digital therapeutics to enable precision dosing.


Team

TH

Tom Hall

Senior Investment Manager


Recent investments

Series A
£3.0M

The funding round was led by The Yield Lab, STIHL Ventures, and ACF Investors to drive global product growth.

"The Spotta platform built by Robert, Neil and the team delivers a real solution which can completely turn the insect pest control industry on its head. With their smart 24/7 monitoring enabling customers to precision target treatment for the first time. It’s a solution that protects people and crops but also hugely reduces the cost and environmental impact of treatment."
— Tim Mills, Managing Partner
Seed
£7.0M

The pre-series A round was led by Amadeus Capital Partners, Expeditions Fund, and IQ Capital.

"Large-scale, fault-tolerant quantum computing will bring about the technological revolution of our generation. We have built an exceptional team dedicated to the mission of building the quantum networking infrastructure necessary to make this a reality. We are grateful to the investors who share our vision for their support as we scale and commercialise our solution."
— Carmen Palacios, Founder and CEO
Series A
£1.5M

Parkwalk led the follow-on investment round to support the market launch of the company's mental health assessment tool.

"Diagnosing mental health issues correctly in primary care can be difficult, due to time constraints and the fact that mental health conditions can be masked by physical symptoms. Delays in diagnosing—or misdiagnosis—mean that it can take several years for an individual with depression to be correctly diagnosed. For bi-polar disorder the average delay is six to eight years. The consequence of this is that many people suffer unnecessarily from debilitating symptoms that could be successfully treated. It is clear that faster and earlier diagnosis followed by the most appropriate treatment will improve the quality of life of affected individuals, while at the same time relieving pressure on the healthcare system"
— Sabine Bahn, Co-founder
Series A
£4.6M

The investment round was led by Parkwalk Advisors and Foresight Williams Technology EIS Fund.

"The energy efficiency of many products could be greatly improved if they incorporated gas and flow sensors, but companies are unable to do so due to cost, size, or manufacturing constraints. Our vision is to bring flow- and gas-sensing technologies to all these products. This funding round helps us to scale up and bring our vision to reality."
— Andrea De Luca, CEO
Seed
£2.1M

The financing round was backed by IQ Capital, Longwall Venture Partners, Martlet, and Cambridge Angels.

"Having been in stealth mode for several years, this latest fund raising marks a significant milestone for the business and its founders. As well as securing venture capital funding from experienced investors in deep tech and life sciences, we have been able to establish corporate partnerships with international Pharma companies and the NHS, we have also hired a senior management team that represents the very best in talent across healthcare and technology."
— Hakim Yadi, CEO and co-founder